An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Atopic Dermatitis Patients.
Latest Information Update: 20 Nov 2025
At a glance
- Drugs CM 512 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors KeyMed Biosciences
Most Recent Events
- 20 Nov 2025 New trial record